While the global Human Papilloma Virus (HPV) testing market is predicted to grow at a compound annual growth rate (CAGR( of 2.4% over the next 10 years, the European HPV tests market will exhibit much stronger growth at 8.7%, says GlobalData, a leading data and analytics company.
The company’s latest report: ‘Human Papilloma Virus (HPV) Tests – In Vitro Diagnostics Market Analysis and Forecast Model’ shows that this considerable growth is a result of new initiatives such as; favourable government policies, high occurrence rate of HPV infections, and growing cervical cancer screening awareness.
Alison Casey, Medical Devices Analyst at GlobalData comments, “Cervical cancer screening has traditionally been based on cervical cytology. In recent years however, many countries have incorporated HPV tests into their cervical cancer and pre-cancer screening programs.
“It is hoped that HPV screening methods may enable better prevention of the disease; these devices are also highly sensitive and allow for increased screening intervals. In the US, HPV tests are already used for widespread screening of asymptomatic women – aged 30 years and older – and this represents the largest market for this medical device.”
Many European countries have also announced upcoming changes in government policies, which are expected to drive strong growth in their HPV tests markets; these include Germany, Italy, UK, Norway, and Sweden.